PharmaTher Holdings Ltd (TSE:PHRM)
:PHRM
Want to see TSE:PHRM full AI Analyst Report?
Top Page
PharmaTher Holdings Ltd
(PHRM)
Select Model
Select Model
Rating:42Neutral
Price Target:
C$0.05
▼(-47.00% Downside)
Action:Reiterated
Date:05/15/26
The score is held down primarily by weak financial performance (pre-revenue operations, ongoing losses, negative cash flow, and a shrinking equity base), despite improved burn rate and zero debt. Technicals also point to a weak downtrend, while valuation is constrained by negative earnings and no dividend support.
Positive Factors
Zero Debt
Having no reported debt materially lowers financial risk and interest burden, preserving flexibility to fund R&D or clinical programs. Over a multi-month horizon this reduces bankruptcy risk and gives management optionality on financing timing and structure.
Negative Factors
Pre-revenue Operations
The absence of commercial revenue means the business is fully dependent on future clinical success and external financing. Over the coming months this keeps cash runway and milestone delivery as primary risks, constraining strategic autonomy until products generate sales.
Read all positive and negative factors
Positive Factors
Negative Factors
Zero Debt
Having no reported debt materially lowers financial risk and interest burden, preserving flexibility to fund R&D or clinical programs. Over a multi-month horizon this reduces bankruptcy risk and gives management optionality on financing timing and structure.
Read all positive factors
PharmaTher Holdings Ltd (PHRM) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$5.46M
Dividend YieldN/A
Average Volume (3M)158.34K
Price to Earnings (P/E)―
Beta (1Y)-0.32
Revenue GrowthN/A
EPS Growth26.95%
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.01
Shares Outstanding91,019,066
10 Day Avg. Volume117,358
30 Day Avg. Volume158,340
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)16.46
Price to Sales (P/S)0.00
P/FCF Ratio-13.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)C$83.60M
PharmaTher Holdings Ltd Business Overview & Revenue Model
Company Description
PharmaTher Holdings Ltd. operates as a clinical-stage biotechnology firm, primarily focused on psychedelic compounds. It is dedicated to investigating, advancing, and bringing to market innovative applications, formulations, and administration tec...
How the Company Makes Money
null...
PharmaTher Holdings Ltd Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
44
Neutral
Cash Flow
22
Negative
| Breakdown | Aug 2025 | Aug 2024 | Aug 2023 | Aug 2022 | Aug 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -711.00 | -1.42K | -1.78K | -355.00 |
| EBITDA | -1.52M | -3.04M | -3.96M | -3.96M | -2.43M |
| Net Income | -1.53M | -3.12M | -6.42M | -4.01M | 2.66M |
Balance Sheet | |||||
| Total Assets | 1.34M | 2.59M | 6.31M | 12.16M | 5.94M |
| Cash, Cash Equivalents and Short-Term Investments | 1.12M | 2.30M | 6.25M | 12.12M | 5.88M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 366.33K | 252.90K | 892.48K | 330.32K | 361.06K |
| Stockholders Equity | 973.54K | 2.34M | 5.42M | 11.83M | 5.58M |
Cash Flow | |||||
| Free Cash Flow | -1.21M | -3.52M | -3.24M | -3.51M | 917.92K |
| Operating Cash Flow | -1.21M | -3.52M | -3.24M | -3.51M | 922.19K |
| Investing Cash Flow | 0.00 | -300.00K | 0.00 | 0.00 | 214.77K |
| Financing Cash Flow | 0.00 | 35.00K | 0.00 | 9.89M | 1.25M |
PharmaTher Holdings Ltd Technical Analysis
Negative
0.10
Price Trends
0.07
Negative
0.08
Negative
0.13
Negative
Market Momentum
>-0.01
Positive
42.58
Neutral
11.11
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PHRM, the sentiment is Negative. The current price of 0.1 is above the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.07, and below the 200-day MA of 0.13, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.58 is Neutral, neither overbought nor oversold. The STOCH value of 11.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:PHRM.
PharmaTher Holdings Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | C$13.55M | -5.98 | 64.41% | ― | ― | -3.16% | |
43 Neutral | C$11.33M | -7.11 | 19.14% | ― | ― | 66.11% | |
42 Neutral | C$5.46M | -4.97 | -112.32% | ― | ― | 26.95% | |
41 Neutral | C$5.46M | -2.46 | ― | ― | ― | ― | |
| ― | C$2.04M | -0.62 | ― | ― | ― | 25.09% |
* Healthcare Sector Average
TSE:PHRM
PharmaTher Holdings Ltd
0.06
-0.17
-73.91%
TSE:CSCI
COSCIENS Biopharma
2.86
-2.17
-43.14%
TSE:KNE
Kane Biotech
0.03
-0.03
-50.00%
TSE:BETR
BetterLife Pharma
0.07
-0.02
-22.22%
TSE:BIOV
BioVaxys Technology
0.07
-0.33
-82.46%
TSE:MRVL
Marvel Biosciences Corp
0.22
0.09
67.97%
PharmaTher Holdings Ltd Corporate Events
Business Operations and StrategyProduct-Related Announcements
PharmaTher Files U.S. Patent to Bolster Peptide Microneedle Patch Platform
Positive
Apr 13, 2026
PharmaTher has filed a U.S. provisional patent application for stabilized peptide compositions designed for microneedle and transdermal delivery, aiming to protect peptides from degradation during manufacturing, drying, storage and use. The patent...
Business Operations and StrategyProduct-Related Announcements
PharmaTher Unveils PatchPrint 3D Microneedle Patch Platform and Commercialization Push
Positive
Mar 26, 2026
PharmaTher Holdings has introduced PatchPrint, an automated tabletop 3D printer for microneedle patches, and filed a provisional U.S. patent for the system. The company aims to evolve from a product-focused developer into a broader microneedle pat...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.